Emerging natural killer cell immunotherapies: Large-scale ex vivo production of highly potent anticancer effectors (Q37796523)

23 August 2017

title

Emerging natural killer cell immunotherapies: large-scale ex vivo production of highly potent anticancer effectors (English)

1 reference

23 August 2017

Emerging natural killer cell immunotherapies: Large-scale ex vivo production of highly potent anticancer effectors (English)

1 reference

https://api.crossref.org/works/10.1016/S1658-3876(10)50024-4

25 July 2024

1 reference

1

Garnet Suck

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20890071

25 July 2024

2

Mickey Boon Chai Koh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20890071

25 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20890071

25 July 2024

publication date

1 January 2010

1 reference

full work available at URL

23 August 2017

https://doi.org/10.1016/s1658-3876(10)50024-4

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20890071

https://api.elsevier.com/content/article/PII:S1658387610500244?httpAccept=text/xml

25 July 2024

1 reference

https://api.crossref.org/works/10.1016/S1658-3876(10)50024-4

https://api.elsevier.com/content/article/PII:S1658387610500244?httpAccept=text/plain

25 July 2024

1 reference

https://api.crossref.org/works/10.1016/S1658-3876(10)50024-4

Hematology/oncology and stem cell therapy

25 July 2024

published in

1 reference

23 August 2017

volume

3

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

135-142

1 reference

Human natural killer cells

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Human natural killer cell development

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination.

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Human natural killer cell receptors: insights into their molecular function and structure

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

NK cells: a lesson from mismatched hematopoietic transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

HLA-haploidentical stem cell transplantation for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

The role of natural killer cells in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Immunotherapy of AML: future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Infrastructure development for human cell therapy translation.

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Stem cell transplantation programme at Singapore General Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Interleukin-2: inception, impact, and implications

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Natural killer cell-based immunotherapy in cancer: current insights and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Interleukin-2 augments natural killer cell activity

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Novel approaches using natural killer cells in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Interleukin-2 and interleukin-15: immunotherapy for cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Should natural killer cells be expanded in vivo or ex vivo to maximize their therapeutic potential?

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Natural killer alloeffector responses in haploidentical hemopoietic stem cell transplantation to treat high-risk leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Natural killer cell consolidation for acute myelogenous leukemia: a cell therapy ready for prime time?

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Regulation of cellular therapies: the Australian perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT).

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Cytokine-induced NK-like T cells: from bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Feeder cells enhance oncolytic and proliferative activity of long-term human bone marrow interleukin-2 cultures and induce different lymphocyte subsets

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Expansion and activation of natural killer cells for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Ex vivo expansion of natural killer cells for clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Replicative potential of human natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Cytotoxicity of activated natural killer cells against pediatric solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

1 reference

7 January 2021

Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15.

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Generation of natural killer cells from serum-free, expanded human umbilical cord blood CD34+ cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Determinants of antileukemia effects of allogeneic NK cells

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

1 reference

https://api.crossref.org/works/10.1016%2FS1658-3876%2810%2950024-4

7 January 2021

Challenges associated with the development, manufacturing, and delivery of cellular medicines

13

1 reference

https://api.crossref.org/works/10.1016/S1658-3876(10)50024-4

Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes

25 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/S1658-3876(10)50024-4

Interleukin-2 in the treatment of renal cancer

25 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/S1658-3876(10)50024-4

Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2

25 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/S1658-3876(10)50024-4

Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

25 July 2024

40

1 reference

https://api.crossref.org/works/10.1016/S1658-3876(10)50024-4

Regulatory aspects of cellular therapy product in Europe: JACIE accreditation in a processing facility

25 July 2024

45

1 reference

https://api.crossref.org/works/10.1016/S1658-3876(10)50024-4

Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy

25 July 2024

50

1 reference

https://api.crossref.org/works/10.1016/S1658-3876(10)50024-4

Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors

25 July 2024

84

1 reference

https://api.crossref.org/works/10.1016/S1658-3876(10)50024-4

25 July 2024

Identifiers

1 reference

23 August 2017

1 reference